Endogenous Kinase Antagonist Complexes for Tissue-Specific Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current kinase inhibition therapies, such as those using exogenous agents and antibodies, are limited in effectively targeting multiple kinase genes involved in conditions like cancer, autoimmune diseases, and transplant rejection, as they may not fully address the over, up, or mis-regulation of kinase enzymes across various tissues.
Innovation Solution
The development of an agent/target cell complex that administers therapeutically effective amounts of agents to downregulate kinase-producing genes in tissues, potentially using multiple agents to form different complexes that induce endogenous production of antagonists and regulatory molecules to specifically target and reduce kinase activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If exogenous kinase inhibitors are administered to treat conditions resulting from kinase over-regulation, then kinase activity can be inhibited, but the therapy may not effectively target multiple kinase genes across various tissues
Solution Approach 1:
The patent divides the therapeutic approach into multiple separate agents, each specifically designed to downregulate particular kinase genes. Instead of using a single broad-spectrum inhibitor, the therapy segments the target kinases into individual gene-specific agents that can be administered together to achieve comprehensive coverage across multiple tissues and kinase types.
Solution Approach 2:
The patent creates a universal therapeutic platform where multiple agents with different specificities can be combined in a single treatment regimen. Each agent maintains its gene-specific function while collectively providing broad-spectrum kinase inhibition across various tissues, achieving both specificity and versatility simultaneously.
2Adaptability or versatility
If multiple agents are administered to form different agent/target cell complexes to downregulate multiple kinase genes, then comprehensive kinase inhibition is achieved, but the complexity of the treatment regimen increases
Solution Approach 1:
The patent merges multiple gene-specific agents into a single combined therapy regimen. By administering multiple agents simultaneously or in coordinated sequences, the treatment achieves comprehensive kinase inhibition without requiring complex separate treatment protocols, simplifying the overall management while maintaining broad coverage.
Data Source
AI summary
The present disclosure relates to one or more agents, therapies, treatments, and methods of use of the agents and/or therapies and/or treatments for selectively inhibiting one or more kinases in one or more tissues. Embodiments of the present disclosure can be used as a therapy or a treatment for a subject where the selective inhibition of kinases with endogenously produced antagonists of kinases may be useful in treating conditions such as cancer, autoimmune disease, and transplant rejection.